StockData

Yarrow Bioscience, Inc. (YARW) stock

YARWNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 11/30102% above fair value
$14.21+0.28 (+2.01%)

Close on Nov 17, 2026Market cap $37.94MP/E –Yield –

Yarrow Bioscience total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Yarrow Bioscience's total debt was $0 at Dec 31, 2021. For fiscal 2021 it was $0, down 100.0% from the year before.

Annual total debt

PeriodPeriod endValueChange
FY2021Dec 31, 2021$0-100.0%
FY2020Dec 31, 2020$33.17M+1.4%
FY2019Dec 31, 2019$32.73M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2021Dec 31, 2021$0-100.0%
Q3 FY2021Sep 30, 2021$0-100.0%
Q2 FY2021Jun 30, 2021$33.38M+1.4%
Q1 FY2021Mar 31, 2021$33.27M+1.4%
Q4 FY2020Dec 31, 2020$33.17M+1.4%
Q3 FY2020Sep 30, 2020$33.02M–
Q2 FY2020Jun 30, 2020$32.92M–
Q1 FY2020Mar 31, 2020$32.82M–
Q4 FY2019Dec 31, 2019$32.73M–

More Yarrow Bioscience figures

See a number that looks wrong?